criteria (Golan et al., 1989; Navot et al., 1992) . These include massive ascites or hydrothorax in conjunction with prominent dyspnoea, haemodynamic instability, oliguria, anasarca, liver dysfunction, adult respiratory distress syndrome (ARDS), acute renal failure, or thromboembolic phenomena.
During the period of this study, a total of 73 492 IVF cycles were performed, 2902 patients were admitted for moderate OHSS, and 209 for severe OHSS. Among the latter, 163 patients (78%) were undergoing IVF, while the rest received conventional ovulation induction treatments. Most patients (94%) with severe OHSS undergoing IVF received ovulation induction by the long protocol using pituitary suppression with GnRH analaogues, followed by exogenous gonadotrophins; 78% with an combination of folicle stimulating hormone/ luteinizing hormone (FSH/LH), and 22% with pure FSH. Of the patients 13% received albumin as a preventive measure for OHSS following oocyte retrieval. Table I shows the main signs and symptoms recorded in the study patients. Most patients presented with ascites (99%), dyspnoea (92%), haemoconcentration (95%), and gastrointestinal disturbances (54%). Oliguria was reported in 62 patients (30%), whereas massive pleural effusion appeared in 19%. Peripheral oedema occurred in 13% and thromboembolism in 2%. Five more patients (2%) had ARDS and three (1%) exhibited acute renal failure. Of the patients, 99% required therapeutic abdominal or thoracic paracentesis for alleviation of dyspnoea or oliguria.
The annual distribution of IVF/embryo transfer cycles, and of severe OHSS is presented in Figure 1 . While the number of severe OHSS cases following conventional ovulation induction treatments remained unchanged, the number of cases following IVF increased dramatically from 2 (0.06% of all IVF cycles) in 1987 to 41 (0.24% of all IVF cycles) in 1996. The total number of IVF cycles performed in Israel during this time period also increased from 2890 in 1987 to 17 283 in 1996.
Thus, during the period of the study, IVF has become the main cause of severe OHSS in Israel, and its expansion dictated a parallel rise in severe OHSS numbers. However, the increase in the incidence of severe OHSS has surmounted that of total IVF activity (20-fold versus six-fold respectively), indicating a substantial rise in the risk for severe OHSS per IVF cycle from 0.06 to Ͼ0.2% (Figure 2) .
Since the prevalence of infertility and anovulation has not changed significantly during the period of the study, these results reflect two important trends: increased use of extracorporeal fertilization techniques, and a more liberal use of ovulation induction medications, both of which may be held responsible for the impressive rise in severe OHSS numbers.
The first trend may be explained by the technical improvement in laboratory facilities and the advent of micromanipula- tion techniques which lead to higher conception rates and thus higher popularity of assisted reproductive methods. This trend may also be attributed to the multitude of severe male infertility couples who until recently would not have been candidates for any fertility treatment but today can be managed successfully by these methods. Nevertheless, the above explanations cannot fully justify the substantial rise in severe OHSS rates described in this report. No doubt the over-utilization of high-dose gonadotrophin protocols by assisted reproductive units today carries some responsibility for this phenomenon. These units seem to have become more competitive during the last few years, with oocyte and embryo numbers being considered as main criteria for their success. With recent refinements in embryo and oocyte cryopreservation, facilitating repeat embryo transfers, these numbers have become even more important in terms of overall pregnancy rates. Expansion of oocyte donation programmes where high-dose gonadotrophin regimens play a key-role in achieving maximal numbers of oocytes for donation may have also contributed their part to this trend. Another possible explanation for this phenomenon is the increasing prevalence of ovulation induction protocols which practise pituitary suppression with a GnRH analogue. These protocols have gained popularity owing to their higher conception and lower cancellation rates (Fleming et al., 1988) . However, these protocols have been associated with a higher risk of OHSS (Forman et al., 1990) . Of the patients with severe OHSS described in our report, 94% were treated with one of these protocols.
Since the incidence of severe OHSS in Israel as presented in this study is lower than that reported worldwide (see above), this phenomenon may be even more serious in other parts of the world. In fact, over-utilization of ovulation induction medication by IVF units worldwide has been suggested previously (Edwards et al., 1996 (Edwards et al., , 1997 with respect not only to OHSS but also to other undesired consequences, such as multiple pregnancies and increased costs.
Hence, we should ask ourselves how far we are willing to go in treating infertility, and where we should draw the line so that life is not endangered. Various prophylactic methods, e.g. i.v. albumin (Orvieto and Ben-Rafael, 1998) or coasting (Lee et al., 1998) , do not appear to reliably prevent OHSS in all cases. Thus, revision of the eligibility criteria for extracorporeal fertilization treatments as well as serious reconsideration of the currently used ovulation induction regimens, especially those with GnRH analogue pituitary suppression, are strongly recommended.
